This is a type of cancer that develops in the lining of organs that produce fluid, like the urinary bladder, ureters, and kidneys. The name 'transitional' refers to the fact that these cells can change shape depending on the amount of fluid they contain. It's the most common type of bladder cancer.
Every report comes from a Lived member, sent anonymously.
Have you had Transurethral Resection of Bladder for Transitional Cell Carcinoma?
Transitional cell carcinoma, now usually called urothelial carcinoma, is cancer that starts in the cells lining the inside of the urinary tract. This lining, the urothelium, stretches as urine collects and shrinks as it empties. It covers the bladder, the ureters (the tubes that carry urine down from the kidneys), the renal pelvis (the funnel at the center of each kidney where urine gathers) and the urethra. Most cases start in the bladder, and urothelial carcinoma is by far the most common type of bladder cancer. The most common sign is blood in the urine. It may look pink, rusty or red, or show up only on a urine test, and it can appear once and then not return for weeks, which makes it easy to dismiss. Other symptoms include needing to urinate often or urgently, burning when urinating and, for tumors in the kidney or ureter, back or side pain that doesn't go away. Early tumors may cause no symptoms at all. Because the entire lining is bathed in the same urine, someone who has had one urothelial tumor has a higher chance of another, either in the same place or elsewhere in the urinary tract. That shapes how the disease is diagnosed and followed. Urothelial cancer of the renal pelvis is also distinct from renal cell carcinoma, the more common kidney cancer, which is treated differently.
Smoking is the most important risk factor. Chemicals from tobacco are absorbed into the blood, filtered out by the kidneys and concentrated in urine, where they sit against the lining of the bladder and can damage the DNA of its cells. Long-term workplace exposure to certain dyes, paints, metals, petroleum products and chemicals used in making rubber, leather, textiles and plastics also raises risk. Risk rises with age, and in the United States the disease is more common in men than women. Other contributors include past radiation to the pelvis, past treatment with the chemotherapy drugs cyclophosphamide or ifosfamide, herbal products containing aristolochic acid, high arsenic levels in well water and long-term use of urinary catheters. Heavy use of certain older pain medicines, such as phenacetin, is linked to cancers of the renal pelvis and ureter. A family history, and some inherited conditions such as Lynch syndrome (best known for raising the risk of colon and uterine cancer), can also increase risk. These are risk factors rather than certain causes. Many people with them never develop this cancer, and some people develop it with no known risk factor.
Evaluation usually starts with a urine sample checked for blood, infection and abnormal cells. Infections and kidney stones are common causes of blood in the urine, so testing helps sort out what is responsible. If cancer is possible, a urologist (a specialist in the urinary tract) performs a cystoscopy, passing a thin tube with a light and lens through the urethra to look at the lining of the bladder. Suspicious areas are sampled for a biopsy, often by removing the tumor through the scope in a procedure called transurethral resection, which can be both the diagnosis and the first treatment. A day or two of blood in the urine or burning afterward is common. A CT urogram, a CT scan taken before and after contrast dye is injected into a vein, shows the kidneys, ureters and bladder together. This matters because tumors can be present in more than one place. If the upper urinary tract looks abnormal, ureteroscopy passes a thinner scope up into the ureter and kidney to see and sample it. Urine cytology, which looks for cancer cells under a microscope, adds information but does not replace a direct look. The pathology report gives two findings that steer treatment. Grade describes how abnormal the cells look: low-grade tumors rarely invade deeper but often come back, while high-grade tumors are more likely to spread. Stage describes how far the cancer has grown. In the bladder, the key dividing line is the muscle layer of the wall. Non-muscle-invasive cancer stays in the lining or the connective tissue just beneath it; muscle-invasive cancer has reached the muscle or beyond. CT or MRI scans, a chest x-ray and sometimes a bone scan check whether it has spread.
Treatment depends mainly on where the tumor is, its grade and how deeply it has grown. For non-muscle-invasive bladder cancer, transurethral resection removes the visible tumor. Because this form often returns, many people then have intravesical therapy: medicine placed directly into the bladder through a thin catheter, held for a while and then passed in the urine. The most common is BCG (bacillus Calmette-Guérin), a weakened bacterium related to the one that causes tuberculosis, which stirs up the immune system in the bladder lining so it attacks remaining cancer cells. It is usually given weekly for 6 weeks and, for higher-risk tumors, continued less often for up to 3 years. Flu-like symptoms, bladder burning and frequent urination for 2 to 3 days after a dose are common. Chemotherapy drugs such as mitomycin or gemcitabine can be placed in the bladder instead. A single small low-grade tumor may need only resection and regular checks. When high-risk cancer keeps returning despite BCG, options include removing the bladder or newer treatments placed in the bladder or given by vein. Muscle-invasive cancer is more likely to spread, so treatment targets the whole bladder and any cancer cells that may already have escaped. A common approach is chemotherapy containing cisplatin followed by radical cystectomy, removal of the bladder and nearby lymph nodes. Giving chemotherapy first has been shown to help people live longer than surgery alone. In men the prostate and seminal vesicles are removed as well; in women the uterus, ovaries and part of the vagina may be. The surgeon then creates a urinary diversion, a new way to store and pass urine, such as an opening on the abdomen that drains into a bag. Pembrolizumab (Keytruda), an immunotherapy, combined with enfortumab vedotin (Padcev), an antibody that carries a chemotherapy drug into cancer cells, is another option before and after surgery, particularly for people who cannot take cisplatin. For people who cannot have or prefer to avoid cystectomy, bladder-preserving treatment combines a thorough resection with radiation and chemotherapy, followed by lifelong cystoscopy checks. Cancer of the renal pelvis or ureter is most often treated with nephroureterectomy, removal of the kidney, its ureter and the small cuff of bladder where the ureter joins. Because this takes away a kidney, the health of the other kidney weighs heavily in the decision. For a superficial tumor in the lower part of the ureter, removing only that section may be enough, and other kidney-sparing approaches are used selectively. When cancer has spread beyond the urinary tract, surgery usually cannot remove it all and medicines become the main treatment. Options include pembrolizumab with enfortumab vedotin, cisplatin-based or other chemotherapy, the immunotherapy nivolumab with chemotherapy, chemotherapy followed by the immunotherapy avelumab, and targeted drugs for tumors with particular gene changes found on biomarker testing. At this stage cancer is very hard to eliminate completely, so treatment aims to control it, relieve symptoms and help people live longer. Clinical trials are an option at every stage.
The outlook depends mainly on stage. Non-muscle-invasive bladder cancer often comes back after treatment, sometimes more than once. Low-grade tumors rarely become invasive, while high-grade tumors and flat carcinoma in situ carry a real risk of growing deeper. For many people this becomes a long-term condition managed with regular cystoscopy and, when needed, another resection or course of bladder treatment. Follow-up is part of the treatment. Most experts recommend exams and tests about every 3 to 6 months at first for people with no sign of cancer, becoming less frequent as time passes without new tumors. Because the whole lining remains at risk, follow-up may include urine tests and imaging of the kidneys and ureters, and people treated for cancer of the kidney or ureter need regular bladder checks too. Urine marker tests can help, but none has replaced cystoscopy. Removing the bladder changes how urine leaves the body, and learning to manage a stoma or another type of diversion takes time and practical training. Because nearby reproductive organs are often removed, the surgery can also affect sexual function and fertility, which are worth raising before surgery rather than after. Bladder-preserving treatment avoids these changes but commits a person to close, ongoing monitoring. People who keep smoking appear more likely to have their cancer return, so stopping is worthwhile at any point. For cancer that has spread, treatment typically continues as long as it is working and tolerated, with regular scans to check its effect.
See a doctor about any blood in the urine, even a single episode that goes away on its own, and about ongoing urinary frequency, burning, or back or side pain without a clear cause such as an infection. People who have been treated should keep their surveillance appointments and report new blood in the urine between visits rather than waiting. During BCG treatment, a few days of flu-like symptoms are expected, but a high fever that doesn't go away can be a sign of a rare, serious BCG infection; call the care team right away. Being suddenly unable to pass urine, which can happen when a tumor blocks the flow, needs emergency medical treatment right away.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Transitional Cell Carcinoma is like, what's helped you, or ask the community a question.